PRO-XTEN dual masking aims to keep the engager inactive in circulation, activate within tumor protease-rich microenvironments ...
Morning Overview on MSN
Study maps prostate immune niches, finds T cells linger for months
Prostate cancer has long frustrated immunologists. Checkpoint inhibitors that unleash the immune system against tumors in the ...
FORT MYERS, Fla., Jan. 22, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is among the first oncology providers in Florida selected to enroll patients in a phase 3 ...
Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one agent shown to shrink tumors in patients whose disease had resisted every ...
Investigators from the UCLA Health Jonsson Comprehensive Cancer Center presented new research at the European Society for Medical Oncology (ESMO) Congress, covering advances in immunotherapy, targeted ...
Super-enhancers (SEs) are large clusters of transcriptional regulatory elements that drive oncogene expression, maintain ...
Combination therapy led to complete remission in more than 50% of mice with different tumor types, many of which were resistant to ICB therapy alone.
A new drug candidate has been developed that simultaneously blocks the proteins regulating cancer growth and metastasis. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results